MULTIMODAL DIAGNOSTICS IN GLIOBLASTOMA: A COMPREHENSIVE REVIEW
Keywords:
Glioblastoma (GBM), Multimodal MRI, Perfusion-Weighted Imaging (PWI), Diffusion-Weighted Imaging (DWI), Amino Acid PET, IDHwildtype, MGMT Promoter Methylation, WHO CNS5 Classification, Immunohistochemistry (IHC), Molecular Diagnostics.Abstract
Glioblastoma (GBM) is a highly aggressive and heterogeneous primary brain tumor. Accurate diagnosis is essential for effective treatment planning and distinguishing true tumor progression from treatmentinduced pseudoprogression.
References
1. Cha, S. (2017). Multi-parametric MRI in glioma imaging and radiomics.
Neuro-Oncology, 19(Suppl 2), ii38–ii50.
2. Kickingereder, P., et al. (2016). Radiomic MRI signature reveals three
distinct subtypes of glioblastoma with different clinical and molecular
characteristics. Clinical Cancer Research, 22(11), 2751–2761.
3. Tsolaki, E., Papadaki, E., & Karantanas, A. (2021). Advanced MRI for
Glioblastoma: Clinical Utility and Future Directions. AJR. American Journal
of Roentgenology, 216(5), 1209–1221.
4. Essig, M., et al. (2013). Perfusion MRI: Current concepts and clinical
applications in gliomas. Radiology, 268(2), 342–356.
5. Pope, W. B., et al. (2005). MR imaging correlates of survival in patients
with high-grade gliomas. AJNR. American Journal of Neuroradiology,
26(10), 2466–2474.
6. Molina, D. C., Ambrosi, C., & Weller, M. (2021). Machine learning and
glioma diagnostics: Emerging concepts. The Lancet Digital Health, 3(7),
e409–e410.
7. Bette, S., et al. (2017). Radiogenomics of glioblastoma: Machine learningbased MRI texture analysis vs. molecular genetics. Journal of NeuroOncology, 135(3), 633–640.
8. Yan, H., et al. (2009). IDH1 and IDH2 mutations in gliomas. The New
England Journal of Medicine (NEJM), 360(8), 765–773.
9. Kresak, J. L., & Price, S. J. (2018). Diffusion MR imaging in high-grade
gliomas: A diagnostic and monitoring tool. Neuro-Oncology Practice, 5(4),
247–258.
10.Ellingson, B. M. (2015). Prognostic imaging biomarkers in glioblastoma.
AJNR. American Journal of Neuroradiology, 36(6), 835–840.
11.Lin, E. L., et al. (2017). MGMT promoter methylation and radiogenomic
signatures in glioblastoma. Neuro-Oncology, 19(9), 1270–1279.
12.Miller, A. M., et al. (2019). Tracking tumor evolution via circulating tumor
DNA in glioma. Nature Medicine, 25(10), 1459–1462.
13.Wang, Y., et al. (2015). Detection of tumor-derived DNA in cerebrospinal
fluid of glioma patients. Science Translational Medicine, 7(304), 304ra136.
14.Zhang, R., et al. (2020). Noninvasive prediction of MGMT promoter
methylation in glioblastoma using radiomics. European Radiology, 30(11),
6210–6219.
15.Park, J. E., et al. (2019). Deep learning MRI predicts IDH and 1p/19q
status in gliomas. Radiology, 291(3), 745–754.